Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2003

View Archived Issues

Intensive intravenous insulin in the management of severe neurological lesions

Novel therapeutic applications suggested for donepezil in neurological disorders

Erlosamide safe and effective in reducing the frequency of partial seizures

Synergistic effect found for pravastatin on the anticoagulant action of LMWH

Rosuvastatin more effective than other statins in hypercholesterolemia

Good safety profile described for an adenovirus-VEGF construct in advanced coronary disease

Use of the tetrapeptide ITF-1697 in acute myocardial infarction

Effect of vardenafil on exercise tolerance in stable angina pectoris

Once-daily extended-release niacin safe and effective in dyslipidemia

Novel DNA polymerase inhibitors for use in herpesvirus infection and related complications

New antibacterial agents in early development at AstraZeneca

Novel antitumor agents prepared and tested at Yamanouchi

Agents with dual activity as angiotensin II antagonists and ACAT inhibitors discovered at Pola

Pyrazolopyridines claimed for herpesvirus infections

Schering-Plough designs novel CCR5 antagonists for HIV infection and other uses

Merck and Isis scientists describe new agents for hepatitis C with NS5B-based mechanism

Axcan makes all-cash offer for Salix

Telik and Roche form drug discovery collaboration

La Jolla closes Riquent follow-on study

Gilead reports 96-week data for Hepsera in hepatitis B

Sumitomo and Mitsui call off consolidation talks

Genentech reports milestones from the first quarter of 2003

Cytotoxicity of F-11782 associated with induction of apoptosis

IB-MECA demonstrates potential therapeutic efficacy in murine models of colitis

AP-158 advances toward clinical trials as a topical antibiotic

Selective GluR5 antagonists as potential antimigraine agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...